LeonaBio (LONA) Other Non-Current Liabilities (2019 - 2026)
LeonaBio (LONA) posted quarterly Other Non-Current Liabilities of $1.2 million for Q1 2026, down 13.03% quarter-over-quarter from $1.4 million in Q4 2025.
LeonaBio (LONA) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Other Non-Current Liabilities for 3 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (changed N/A YoY), while the FY2025 annual figure was $1.4 million, changed N/A from the prior year.
- Other Non-Current Liabilities slipped to $1.2 million in Q1 2026 per LONA's latest filing, from $1.4 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.4 million in Q4 2025 and bottomed at $1.2 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.22 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2019 | 999,000.00 |